Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi

Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...

Sanofi to buy Provention Bio in deal worth $2.9 billion

French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with a...

Maria Marino Discusses Leaving SNY For Action Network

Journalist Maria Marino interviews Connecticut women’s basketball coach Geno Auriemma. Photo via Maria Marino After nearly five years as a do-it-all reporter and on-air presence for SNY, Maria M...

Covid-19 Vaccine Makers Face a New Rival as GlaxoSmithKline and Sanofi Prepare to Enter the Ring

As new Covid-19 cases fall, the postpandemic vaccine market grows more interesting. On Wednesday, GlaxoSmithKline and Sanofi, two of the world’s largest vaccine makers, said they would submit a Covid ...

AscendEX Lists the Synthetify Token, SNY

AscendEX is excited to announce the listing of the Synthetify token, SNY, under the trading pair SNY/USDT on the AscendEX platform, starting January 25 at 2 p.m. UTC.  Synthetify is a multi-collateral...